Amin U. Haq, MD
This content is PDF only. Please click on the PDF icon to access.
To the Editor: In his excellent review (1) of tamoxifen in the treatment of breast cancer, Legha concludes that "adjuvant use of tamoxifen in premenopausal women with stage II breast cancer has not been shown to be useful and should be avoided." As the author himself has noted, the Nolvadex Adjuvant Treatment Organization (NATO) and Scottish Cancer Trial Group have shown that the adjuvant use of tamoxifen improved the disease-free and overall survival of premenopausal women (2, 3). The number of premenopausal patients with stage II breast cancer in the Scottish trial was not stated; however, all premenopausal women in
Haq AU. Tamoxifen and Premenopausal Breast Cancer. Ann Intern Med. 1988;109:992–993. doi: https://doi.org/10.7326/0003-4819-109-12-992_2
Download citation file:
Published: Ann Intern Med. 1988;109(12):992-993.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use